Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of “Hold” by Analysts

Shares of Pfizer Inc. (NYSE:PFE) have been assigned an average rating of “Hold” from the twenty analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $28.5882.

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Monday. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Finally, Wolfe Research reiterated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being highlighted as a low-valuation healthcare name, with one article calling it a “dirt cheap” stock to buy in July as investors look for cash-generative Big Pharma franchises trading at bargain multiples. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer received new FDA approval for IBRANCE in HER2-positive breast cancer, adding a fresh catalyst and potentially extending the drug’s commercial relevance. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Cantor Fitzgerald reaffirmed Pfizer at Neutral and maintained a $27 price target, implying room above the recent trading level. Pfizer rating reaffirmed by Cantor Fitzgerald
• Neutral Sentiment: Pfizer Limited separately announced a July 28 virtual AGM and proposed a final dividend, but this appears to refer to the India-listed Pfizer Limited rather than Pfizer Inc. Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend
• Negative Sentiment: Analysts and media reports said Pfizer’s growth story is being delayed by pipeline timing issues, leadership uncertainty, and reduced near-term re-rating potential, contributing to a weaker stock tone. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: Pfizer stock also declined in the latest session as investors rotated into a stronger market, reflecting ongoing skepticism about near-term momentum. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vermillion Wealth Management Inc. raised its position in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares during the period. Triad Wealth Partners LLC boosted its position in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares during the period. Eagle Capital Management LLC grew its stake in shares of Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after buying an additional 390 shares during the last quarter. ETF Store Inc. increased its holdings in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares during the period. Finally, Delta Financial Advisors LLC increased its holdings in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 398 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.7%

Shares of PFE stock traded up $0.41 during mid-day trading on Tuesday, hitting $24.14. The company’s stock had a trading volume of 8,034,024 shares, compared to its average volume of 42,575,844. The stock has a market cap of $137.56 billion, a price-to-earnings ratio of 18.43 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer has a 52-week low of $23.11 and a 52-week high of $28.75. The business has a 50-day moving average price of $25.63 and a 200 day moving average price of $26.23.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the company earned $0.92 EPS. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s payout ratio is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.